Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease

Mohamed Ibrahim, Entesar Farghaly, Wafaey Gomaa, Mina Kelleni, Aly Mohamed Abdelrahman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet. Nitro-aspirin (NO-aspirin) is a new molecule in which aspirin and a NO-donating group are covalently linked. This study investigated the potential protective effect of NO-aspirin on NAFLD. Experimental rats were assigned into 4 groups. Group 1 was fed with normal diet and served as normal control group. Group 2 was fed with 2% cholesterol diet and received vehicle as positive control NAFLD group. Group 3 was fed with 2% cholesterol diet plus NO-aspirin (100 mg/kg/day). Group 4 was fed with 2% cholesterol diet plus aspirin (55 mg/kg/day). Rats were treated for 8 weeks. The results showed that NO-aspirin (but not aspirin) prevented the development of NAFLD as evidenced by significant reduction in liver weight/body weight ratio (liver index) and histopathologic changes. The protective effect of NO-aspirin is accompanied with significant decrease in triglycerides, malondialdehyde (MDA), and nitric oxide (NO) in hepatic tissue. Semi-quantitative immunohistochemical studies showed significant decrease in expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in hepatic tissue. In conclusion, NO-aspirin inhibited multiple pathways involved in the pathogenesis of NAFLD indicating that it might serve as a new therapeutic strategy.

Original languageEnglish
Pages (from-to)289-295
Number of pages7
JournalEuropean Journal of Pharmacology
Volume659
Issue number2-3
DOIs
Publication statusPublished - Jun 1 2011

Fingerprint

Aspirin
Liver
Diet
Cholesterol
Therapeutics
Nitric Oxide
Non-alcoholic Fatty Liver Disease
Nitric Oxide Synthase Type II
Cyclooxygenase 2
Malondialdehyde
Triglycerides
Body Weight
Weights and Measures
Control Groups
Wounds and Injuries

Keywords

  • Aspirin
  • NAFLD
  • NO-aspirin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. / Ibrahim, Mohamed; Farghaly, Entesar; Gomaa, Wafaey; Kelleni, Mina; Abdelrahman, Aly Mohamed.

In: European Journal of Pharmacology, Vol. 659, No. 2-3, 01.06.2011, p. 289-295.

Research output: Contribution to journalArticle

Ibrahim, Mohamed ; Farghaly, Entesar ; Gomaa, Wafaey ; Kelleni, Mina ; Abdelrahman, Aly Mohamed. / Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. In: European Journal of Pharmacology. 2011 ; Vol. 659, No. 2-3. pp. 289-295.
@article{c38421e746de40e9a445387f8697fa59,
title = "Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet. Nitro-aspirin (NO-aspirin) is a new molecule in which aspirin and a NO-donating group are covalently linked. This study investigated the potential protective effect of NO-aspirin on NAFLD. Experimental rats were assigned into 4 groups. Group 1 was fed with normal diet and served as normal control group. Group 2 was fed with 2{\%} cholesterol diet and received vehicle as positive control NAFLD group. Group 3 was fed with 2{\%} cholesterol diet plus NO-aspirin (100 mg/kg/day). Group 4 was fed with 2{\%} cholesterol diet plus aspirin (55 mg/kg/day). Rats were treated for 8 weeks. The results showed that NO-aspirin (but not aspirin) prevented the development of NAFLD as evidenced by significant reduction in liver weight/body weight ratio (liver index) and histopathologic changes. The protective effect of NO-aspirin is accompanied with significant decrease in triglycerides, malondialdehyde (MDA), and nitric oxide (NO) in hepatic tissue. Semi-quantitative immunohistochemical studies showed significant decrease in expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in hepatic tissue. In conclusion, NO-aspirin inhibited multiple pathways involved in the pathogenesis of NAFLD indicating that it might serve as a new therapeutic strategy.",
keywords = "Aspirin, NAFLD, NO-aspirin",
author = "Mohamed Ibrahim and Entesar Farghaly and Wafaey Gomaa and Mina Kelleni and Abdelrahman, {Aly Mohamed}",
year = "2011",
month = "6",
day = "1",
doi = "10.1016/j.ejphar.2011.03.016",
language = "English",
volume = "659",
pages = "289--295",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease

AU - Ibrahim, Mohamed

AU - Farghaly, Entesar

AU - Gomaa, Wafaey

AU - Kelleni, Mina

AU - Abdelrahman, Aly Mohamed

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet. Nitro-aspirin (NO-aspirin) is a new molecule in which aspirin and a NO-donating group are covalently linked. This study investigated the potential protective effect of NO-aspirin on NAFLD. Experimental rats were assigned into 4 groups. Group 1 was fed with normal diet and served as normal control group. Group 2 was fed with 2% cholesterol diet and received vehicle as positive control NAFLD group. Group 3 was fed with 2% cholesterol diet plus NO-aspirin (100 mg/kg/day). Group 4 was fed with 2% cholesterol diet plus aspirin (55 mg/kg/day). Rats were treated for 8 weeks. The results showed that NO-aspirin (but not aspirin) prevented the development of NAFLD as evidenced by significant reduction in liver weight/body weight ratio (liver index) and histopathologic changes. The protective effect of NO-aspirin is accompanied with significant decrease in triglycerides, malondialdehyde (MDA), and nitric oxide (NO) in hepatic tissue. Semi-quantitative immunohistochemical studies showed significant decrease in expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in hepatic tissue. In conclusion, NO-aspirin inhibited multiple pathways involved in the pathogenesis of NAFLD indicating that it might serve as a new therapeutic strategy.

AB - Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury; however its therapeutic strategy has not been established yet. Nitro-aspirin (NO-aspirin) is a new molecule in which aspirin and a NO-donating group are covalently linked. This study investigated the potential protective effect of NO-aspirin on NAFLD. Experimental rats were assigned into 4 groups. Group 1 was fed with normal diet and served as normal control group. Group 2 was fed with 2% cholesterol diet and received vehicle as positive control NAFLD group. Group 3 was fed with 2% cholesterol diet plus NO-aspirin (100 mg/kg/day). Group 4 was fed with 2% cholesterol diet plus aspirin (55 mg/kg/day). Rats were treated for 8 weeks. The results showed that NO-aspirin (but not aspirin) prevented the development of NAFLD as evidenced by significant reduction in liver weight/body weight ratio (liver index) and histopathologic changes. The protective effect of NO-aspirin is accompanied with significant decrease in triglycerides, malondialdehyde (MDA), and nitric oxide (NO) in hepatic tissue. Semi-quantitative immunohistochemical studies showed significant decrease in expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) in hepatic tissue. In conclusion, NO-aspirin inhibited multiple pathways involved in the pathogenesis of NAFLD indicating that it might serve as a new therapeutic strategy.

KW - Aspirin

KW - NAFLD

KW - NO-aspirin

UR - http://www.scopus.com/inward/record.url?scp=79955940888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955940888&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2011.03.016

DO - 10.1016/j.ejphar.2011.03.016

M3 - Article

VL - 659

SP - 289

EP - 295

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -